A Study of CS1001 in Subjects With Stage III Non-Small Cell Lung Cancer

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

381 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-10-26

Study Completion Date

2023-04-03

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a randomized, double-blind, placebo-controlled, multicenter phase III study to evaluate the efficacy and safety of CS1001 in subjects with locally advanced/unresectable (Stage III) non-small cell lung cancer that has not progressed after prior concurrent/sequential chemoradiotherapy.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study of CS1001 in Subjects With Stage IV Non-Small Cell Lung Cancer

NCT03789604

Non Small Cell Lung Cancer

ACTIVE_NOT_RECRUITING PHASE3

A Phase Ia/Ib Study of CS1001 in Subjects With Advanced Solid Tumors

NCT03312842

Advanced Cancer

COMPLETED PHASE1

Safety and Tolerability Evaluation of Low-dose Radiation in Combination With CS1001 in Relapsed SCLC Patients

NCT04421352

Relapsed Small Cell Lung Cancer

COMPLETED PHASE1

A Study of Anti-PD1 Antibody-activated TILs in Non-small Cell Lung Cancer

NCT03903887

Non-small Cell Lung Cancer

UNKNOWN PHASE1/PHASE2

Evaluating Efficacy and Safety of Anlotinib Combined With Concurrent Chemoradiotherapy Followed by Consolidation Immunotherapy for Locally Advanced Non-small Cell Lung Cancer

NCT05481775

Locally Advanced Non-small Cell Lung Cancer Efficacy and Safety

WITHDRAWN PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Non-Small Cell Lung Cancer Stage III

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

CS1001monoclonal antibody

Group Type EXPERIMENTAL

CS1001 monoclonal antibody

Intervention Type BIOLOGICAL

Participant will receive CS1001 monoclonal antibody 1200 mg by intravenous infusion every 3 weeks, for up to 24 months

CS1001 Placebo

Group Type PLACEBO_COMPARATOR

CS1001 placebo

Intervention Type BIOLOGICAL

Participant will receive CS1001 placebo by intravenous infusion every 3 weeks, for up to 24 months

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

CS1001 monoclonal antibody

Participant will receive CS1001 monoclonal antibody 1200 mg by intravenous infusion every 3 weeks, for up to 24 months

Intervention Type BIOLOGICAL

CS1001 placebo

Participant will receive CS1001 placebo by intravenous infusion every 3 weeks, for up to 24 months

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Willing to participate in this trial; fully understand and informed of this trial, and able to provide written informed consent form (ICF).
2. ≥ 18 years of age on the day of signing ICF.
3. Have histologically confirmed locally advanced/unresectable stage III non-small cell lung cancer.
4. The first dose of CS1001 will be administered within 1 - 42 days (including 42 days) after concurrent/sequential chemoradiotherapy is completed.
5. Platinum-containing chemotherapy.
6. Absence of progression after concurrent/sequential chemoradiotherapy.
7. Eastern Cooperative Oncology Group(ECOG) Perfomance Status (PS) of 0 or 1.
8. Life expectancy ≥ 12 weeks.
9. Subject with prior anti-cancer treatment can only be enrolled when all toxicities except for hearing loss, alopecia and fatigue, of prior anti-cancer treatment has recovered to baseline or ≤ Grade 1 (according to National Cancer Institute \[NCI\] Common Terminology Criteria for Adverse Events \[CTCAE\] v4.03).
10. Subjects must have adequate organ function as assessed in the following laboratory tests.
11. Women of childbearing potential or fertile men must agree to use an effective method of birth control from providing signed ICF and for 180 days after last dose of investigational product. Women of childbearing potential include premenopausal women and women whose menopause started within prior 2 years. Women of childbearing potential must have a negative pregnancy test ≤7 days prior to the first dose of experimental drug.

Exclusion Criteria

1. Histologically identified to have mixed small cell lung cancer component.
2. Disease progression after concurrent/sequential chemoradiotherapy.
3. Major surgical procedure (as determined by investigators) within 28 days prior to the first dose of investigational product.
4. Has received a live vaccine within 28 days prior to the first dose of investigational product.
5. Current participation in another clinical study or use of any investigational drug within 28 days prior to the first dose of investigational product in this trial. (Participation in the overall survival follow-up of a study is allowed.)
6. Any prior treatment of antibody/drug that targets at T-cell coregulatory proteins (immune checkpoints, including PD-1, PD-L1, CTLA4, TIM3 and LAG3, etc.).
7. Subjects with current active autoimmune disease or prior history of autoimmune disease that probably will relapse or at risk of having these conditions.
8. Immune deficient disease or systemic corticosteroid treatment within 7 days prior to the first dose of investigational product, or any other form of immune suppressing treatment.
9. A known additional malignancy within 5 years prior to the first dose of investigational product.
10. History of inflammatory bowel disease or active inflammatory bowel disease (for example Crohn's disease or ulcerative colitis).
11. Known history of human immunodeficiency virus (HIV) infection and/or acquired immune deficiency syndrome.
12. Subjects at active phase of chronic hepatitis B or with active hepatitis C.
13. History of organ transplantation.
14. Subjects with known history of alcoholism or drugs abuse.
15. Severe allergic reaction to other monoclonal antibodies.
16. QTc interval \> 480 msec on the screening electrocardiogram (ECG) (as calculated by Fridericia formula).
17. Subjects with other conditions that in the investigator's opinion may influence subject's compliance or make subjects not suitable for participating in this trial.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No